Published in Lancet Oncol on July 16, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol (2015) 2.00
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer (2014) 1.59
Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics. Proteomics (2014) 1.54
MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood (2013) 1.50
Insight into early-phase trials for lung cancer in the United States. Chin J Cancer (2015) 1.46
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
Resistance to RAF inhibitors revisited. J Invest Dermatol (2013) 1.33
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27
Mitogen-activated protein kinases and their role in radiation response. Genes Cancer (2013) 1.26
MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye (Lond) (2015) 1.18
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 1.16
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet (2013) 1.13
Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist (2013) 1.08
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol (2014) 1.07
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? Curr Treat Options Oncol (2017) 1.06
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med (2013) 1.02
Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep (2014) 1.01
Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget (2015) 1.01
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One (2015) 1.01
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer (2015) 0.98
BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell Melanoma Res (2014) 0.94
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One (2014) 0.94
Genomic, prognostic, and cell-signaling advances in uveal melanoma. Am Soc Clin Oncol Educ Book (2013) 0.94
Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. Oncotarget (2015) 0.94
Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma. Mol Diagn Ther (2014) 0.94
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer (2014) 0.93
Genetics of melanoma. Front Genet (2013) 0.91
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res (2014) 0.90
The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst (2016) 0.90
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis (2013) 0.90
Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. Oncotarget (2014) 0.89
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw (2014) 0.86
Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol (2015) 0.86
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol (2013) 0.85
Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res (2014) 0.85
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. Oncotarget (2016) 0.85
Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov (2013) 0.85
Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. Front Immunol (2013) 0.85
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer (2015) 0.85
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Semin Oncol (2015) 0.85
Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors. Transl Oncol (2013) 0.83
Metastatic melanoma - a review of current and future drugs. Drugs Context (2012) 0.83
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. Ann Oncol (2015) 0.83
Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res (2013) 0.82
Drug monographs: dabrafenib and trametinib. Hosp Pharm (2013) 0.82
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol (2014) 0.81
Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag (2016) 0.81
Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther (2014) 0.81
Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through Both Tumor Extrinsic and Intrinsic Activities. Mol Cancer Ther (2016) 0.81
Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res (2015) 0.81
The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol (2015) 0.79
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Oncotarget (2016) 0.79
BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog (2014) 0.79
In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma. Mol Cancer (2015) 0.79
Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther (2015) 0.78
Genotyping of cutaneous melanoma. Chin Clin Oncol (2014) 0.78
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget (2014) 0.78
The coming of age of MEK. Lancet Oncol (2012) 0.78
Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. Clin Cancer Res (2015) 0.78
Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol (2016) 0.77
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget (2016) 0.77
Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann Transl Med (2015) 0.77
Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Des Devel Ther (2014) 0.77
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf (2014) 0.77
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Br J Clin Pharmacol (2014) 0.77
Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nat Commun (2016) 0.77
Development and external validation of a prognostic nomogram for metastatic uveal melanoma. PLoS One (2015) 0.77
Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. Onco Targets Ther (2013) 0.77
A Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity Prediction. PLoS One (2015) 0.77
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. Invest New Drugs (2015) 0.76
Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World J Gastroenterol (2015) 0.76
Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol (2016) 0.76
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget (2015) 0.76
MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. J Invest Dermatol (2015) 0.76
Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. Oncotarget (2015) 0.76
Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Ther Adv Med Oncol (2015) 0.76
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs (2016) 0.76
Neoadjuvant treatment of melanoma: case reports and review. Exp Hematol Oncol (2013) 0.76
Targeted therapies in melanoma. Surg Oncol Clin N Am (2015) 0.76
Steroid Resistance of Airway Type 2 Innate Lymphoid Cells (ILC2s) from Severe Asthma: The Role of Thymic Stromal cell Lymphopoietin (TSLP). J Allergy Clin Immunol (2017) 0.76
The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects. JCI Insight (2016) 0.75
Targeting mutant NRAS signaling pathways in melanoma. Pharmacol Res (2016) 0.75
Clinical presentation and management of uveal melanoma. Mol Clin Oncol (2016) 0.75
Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. Invest Ophthalmol Vis Sci (2014) 0.75
Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer (2016) 0.75
Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients. Neoplasia (2017) 0.75
Induction of exportin-5 expression during melanoma development supports the cellular behavior of human malignant melanoma cells. Oncotarget (2016) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res (2011) 3.36
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog (2004) 3.02
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene (1994) 2.03
Resistance to MEK inhibitors: should we co-target upstream? Sci Signal (2011) 1.66
N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol (1998) 1.15
Mutation and copy number detection in human cancers using a custom genotyping assay. Genomics (2011) 0.90
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol (2008) 5.98
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2011) 4.77
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Molecular target class is predictive of in vitro response profile. Cancer Res (2010) 3.27
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol (2002) 3.25
Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol (2011) 3.19
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Cancer: the road to Amiens. J Clin Oncol (2008) 3.10
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol (2010) 2.84
Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol (2003) 2.83
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Epstein-Barr virus and cancer. Clin Cancer Res (2004) 2.78
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol (2013) 2.63
Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer (2007) 2.62
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol (2009) 2.56
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 2.55
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol (2009) 2.53
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer (2005) 2.49
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45